CARA vs. CYBN, SCPH, RGLS, CTMX, RPTX, GOSS, CRVS, SYRS, OPTN, and ACET
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Cybin (CYBN), scPharmaceuticals (SCPH), Regulus Therapeutics (RGLS), CytomX Therapeutics (CTMX), Repare Therapeutics (RPTX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Cybin (NYSE:CYBN) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.
Cara Therapeutics received 666 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 75.03% of users gave Cara Therapeutics an outperform vote.
Cybin has higher earnings, but lower revenue than Cara Therapeutics. Cybin is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cybin currently has a consensus price target of $5.00, indicating a potential upside of 1,328.57%. Cara Therapeutics has a consensus price target of $11.12, indicating a potential upside of 1,612.35%. Given Cybin's higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Cybin.
In the previous week, Cara Therapeutics had 5 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Cara Therapeutics and 1 mentions for Cybin. Cybin's average media sentiment score of 0.73 beat Cara Therapeutics' score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the news media.
17.9% of Cybin shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cybin has a net margin of 0.00% compared to Cybin's net margin of -723.49%. Cara Therapeutics' return on equity of -109.05% beat Cybin's return on equity.
Cybin has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
Cara Therapeutics beats Cybin on 9 of the 17 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
